The Global Metastatic Melanoma therapeutics Market is estimated to be valued at US$ 8011.15 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Metastatic melanoma therapeutics are drugs used for treating metastatic melanoma, which is the most dangerous type of skin cancer that has spread to other organs of the body. These therapeutics have advantages such as targeted action, improved efficacy and reduced side effects compared to conventional chemotherapy. Effective treatment of metastatic melanoma has become an important health issue.
Market key trends:
One of the key trends in the metastatic melanoma therapeutics market is the increasing demand for precision medicines or targeted therapies. These include targeted immune checkpoint inhibitors and BRAF/MEK inhibitor combinations. These therapies have revolutionized the treatment of metastatic melanoma by improving overall survival and progression-free survival rates compared to chemotherapy. They work by blocking specific molecules involved in tumor growth and progression. The success of targeted therapies has driven research and development of newer precision medicines for metastatic melanoma.
Segment Analysis
Metastatic melanoma therapeutics market is segmented based on therapy into chemotherapy, immunotherapy, targeted therapy, and others. Among these, the immunotherapy segment dominated the market in 2022 due to the rising adoption of immunotherapy drugs for the treatment of metastatic melanoma. Immunotherapy involves using the body's own immune system to fight cancer. It stimulates or restores the ability of the immune system to detect and attack cancer cells. Many promising immunotherapy drugs such as checkpoint inhibitors are being extensively used for metastatic melanoma treatment, thereby driving the segment's growth.
Key Takeaways
The Global Metastatic Melanoma Therapeutics Market is expected to witness high growth, exhibiting a CAGR of 11% over the forecast period, due to increasing prevalence of melanoma and a robust product pipeline.
The US accounted for the largest share of the global metastatic melanoma therapeutics market in 2022 due to the rising incidence of melanoma and availability of advanced treatment options in the country. Europe held the second largest market share owing to the presence of leading pharmaceutical companies and growing R&D activities for melanoma therapies. Asia Pacific is expected to grow at the fastest rate during the forecast period with increasing government initiatives to enhance healthcare infrastructure and rising healthcare expenditure in the region.
Key players operating in the metastatic melanoma therapeutics market include Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Genentech Inc., F. Hoffmann-La Roche AG., Amgen Inc., AstraZeneca, Daiichi Sankyo Company, Limited., AB Sciences., AgonOX, Inc., Eisai Co., Ltd, GlaxoSmithKline, plc., Pfizer, Inc., and Vical, Inc. Major players are focused on developing innovative immunotherapy and targeted drug therapies to expand their product portfolio and strengthen market position.
Read More - https://www.marketwebjournal.com/metastatic-melanoma-therapeutics-market-share-trend- analysis/
